EU: No SPCs For New Uses OF Existing Drugs
Ruling Reverses Court’s 2012 Decision
Executive Summary
A judgment by the Court of Justice of the EU is bad news for innovators seeking supplementary protection certificates to protect new indications for their products, but it could offer new opportunities for generic firms.
You may also be interested in...
Crunch Time For Protection Of New Therapeutic Uses In Europe
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.